EP2322658A1 — Signature for the diagnosis of breast cancer aggressiveness and genetic instability
Assigned to Centre National de la Recherche Scientifique CNRS · Expires 2011-05-18 · 15y expired
What this patent protects
The present invention relates to a method for diagnosing aggressiveness and/or genetic instability of a breast cancer in a patient from a breast cancer sample of said patient, comprising: a) measuring in vitro the expression level of the POLQ gene and the expression level of a co…
USPTO Abstract
The present invention relates to a method for diagnosing aggressiveness and/or genetic instability of a breast cancer in a patient from a breast cancer sample of said patient, comprising: a) measuring in vitro the expression level of the POLQ gene and the expression level of a control gene in said patient breast cancer sample; b) calculating for said POLQ gene an expression level ratio of the expression level of POLQ to the expression of the said control gene in said patient breast cancer sample; c) comparing the said POLQ expression level ratio to a corresponding threshold value, and d) diagnosing breast cancer aggressiveness and genetic instability if the said POLQ expression level ratio is superior to a corresponding threshold values. Dedicated microarrays and kits are also described, as well as a method of selecting a suitable treatment.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.